NNVC Nanoviricides Inc

Price (delayed)

$2.38

Market cap

$28.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.82

Enterprise value

$24.86M

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricideĀ® class of drug candidates are designed to specifically attack enveloped ...

Highlights
NNVC's quick ratio has dropped by 86% year-on-year and by 28% since the previous quarter
The equity has declined by 42% year-on-year and by 14% since the previous quarter

Key stats

What are the main financial stats of NNVC
Market
Shares outstanding
11.81M
Market cap
$28.12M
Enterprise value
$24.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.63
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$9.46M
EBITDA
-$8.7M
Free cash flow
-$6.39M
Per share
EPS
-$0.82
Free cash flow per share
-$0.54
Book value per share
$0.9
Revenue per share
$0
TBVPS
$0.94
Balance sheet
Total assets
$11.46M
Total liabilities
$813,337
Debt
$0
Equity
$10.65M
Working capital
$2.7M
Liquidity
Debt to equity
0
Current ratio
4.32
Quick ratio
4
Net debt/EBITDA
0.37
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-66.5%
Return on equity
-74.7%
Return on invested capital
-124.3%
Return on capital employed
-88.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NNVC stock price

How has the Nanoviricides stock price performed over time
Intraday
3.93%
1 week
15.53%
1 month
30.77%
1 year
46.91%
YTD
133.33%
QTD
38.37%

Financial performance

How have Nanoviricides's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.8M
Net income
-$9.51M
Gross margin
N/A
Net margin
N/A
NNVC's net income is down by 40% YoY
Nanoviricides's operating income has decreased by 39% YoY

Growth

What is Nanoviricides's growth rate over time

Valuation

What is Nanoviricides stock price valuation
P/E
N/A
P/B
2.63
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 39% YoY
The stock's price to book (P/B) is 139% more than its last 4 quarters average of 1.1 and 88% more than its 5-year quarterly average of 1.4
The equity has declined by 42% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Nanoviricides business performance
Nanoviricides's return on equity has shrunk by 127% YoY and by 17% QoQ
NNVC's return on assets has dropped by 107% year-on-year and by 14% since the previous quarter
Nanoviricides's return on invested capital has shrunk by 52% YoY and by 6% QoQ

Dividends

What is NNVC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NNVC.

Financial health

How did Nanoviricides financials performed over time
NNVC's total liabilities has soared by 133% YoY but it is down by 14% QoQ
NNVC's quick ratio has dropped by 86% year-on-year and by 28% since the previous quarter
NNVC's debt is 100% lower than its equity
The equity has declined by 42% year-on-year and by 14% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.